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a  b  s  t  r  a  c  t
Administration  of drugs  via  inhalation  is  an attractive  route  for  pulmonary  and  systemic  drug  delivery.
The therapeutic  outcome  of  inhalation  therapy  depends  not  only  on the  dose  of  the  lung-delivered  drug,
but  also  on  its bioactivity  and regional  distribution.  Fluorescence  imaging  has  the  potential  to  moni-
tor  these  aspects  already  during  preclinical  development  of inhaled  drugs,  but quantitative  methods
of  analysis  are  lacking.  In  this  proof-of-concept  study,  we demonstrate  that  Cryoslicing  Imaging  allows
for  3D  quantitative  ﬂuorescence  imaging  on  ex  vivo murine  lungs.  Known  amounts  of  ﬂuorescent  sub-
stance  (nanoparticles  or  ﬂuorophore–drug  conjugate)  were  instilled  in  the lungs  of mice.  The  excised
lungs  were  measured  by Cryoslicing  Imaging.  Herein,  white  light and  ﬂuorescence  images  are  obtained
from  the  face  of  a gradually  sliced  frozen  organ  block.  A quantitative  representation  of the  ﬂuorescence
intensity  throughout  the  lung  was  inferred  from  the  images  by  accounting  for  instrument  noise,  tissue
autoﬂuorescence  and  out-of-plane  ﬂuorescence.  Importantly,  the out-of-plane  ﬂuorescence  correction
is based  on  the  experimentally  determined  effective  light  attenuation  coefﬁcient  of  frozen  murine  lung
tissue  (10.0  ± 0.6  cm−1 at 716  nm).  The  linear  correlation  between  pulmonary  total  ﬂuorescence  inten-
sity  and  pulmonary  ﬂuorophore  dose  indicates  the validity  of  this  method  and allows  direct  ﬂuorophore
dose  assessment.  The  pulmonary  dose  of  a ﬂuorescence-labeled  drug  (FcR-Alexa750)  could  be assessed
with  an estimated  accuracy  of 9% and  the  limit  of  detection  in  ng regime.  Hence,  Cryoslicing  Imaging  can
be  used  for  quantitative  assessment  of  dose  and  3D  distribution  of  ﬂuorescence-labeled  drugs  or  drug
carriers  in the  lungs  of  mice.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY-NC-SA
license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).. Introduction
Inhalation is a promising route for rapid and non-invasive deliv-
ry of aerosolized therapeutics to the lungs and other target organs.
nhalation therapy is ideally suited for treating lung diseases as
t allows for delivery of drugs directly to the site of action. This
∗ Corresponding author at: Helmholtz Zentrum München, German Research Cen-
er  for Environmental Health, Institute of Lung Biology and Disease, Ingolstädter
andstr. 1, 85764 Neuherberg, Germany. Tel.: +49 8931872557;
ax: +49 8931872400.
E-mail address: otmar.schmid@helmholtz-muenchen.de (O. Schmid).
ttp://dx.doi.org/10.1016/j.jpba.2014.09.001
731-7085/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unminimizes side effects and enables immediate drug action at the
diseased tissue. In addition, the large surface area of the lung
(ca. 70 m2), the highly dispersed nature of an inhaled aerosol and
the good permeability of the alveolar air–blood barrier allow for
rapid transport of small molecules from the lung to other organs
via systemic circulation [1]. Particularly for drugs with poor oral
bioavailability, such as peptides and proteins, the pulmonary route
offers a promising alternative way  of systemic drug delivery [2].
The avoidance of hepatic and intestinal ﬁrst-pass metabolism is an
added beneﬁt of pulmonary drug delivery compared to oral appli-
cation.
Depending on the type of disease, the drug should be targeted to
speciﬁc regions of the lung. For instance, asthma attacks are mainly
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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removed from the animal chest, and the lung was  partially inﬂated
by connecting an OCT-ﬁlled syringe (Tissue Tek Optimal Cutting30 N. Barapatre et al. / Journal of Pharmaceuti
ue to severe bronchial constriction, while lung emphysema is
haracterized by a loss of alveolar septa. Hence, the therapeutic
utcome of inhalation therapy depends not only on lung-delivered
rug dose, but also on the regional distribution (e.g. airways versus
lveoli) and bioactivity of the delivered drug [3,4]. These aspects
hould already be considered during the preclinical development
f inhaled drugs [5,6]. Hence, preclinical methods for detection of
ulmonary dose, spatial distribution and bioactivity of the drug
re required. Radioactive labeling allows for regional dosimetry
ia X-ray tomography (CT), PET and SPECT, but not for determi-
ation of the bioactivity of the substances. On the other hand,
uorescent substances including nanoparticles have been widely
sed for preclinical dosimetry studies both in vitro and in vivo [7,8]
nd numerous ﬂuorescent probes are available for studying the
ioactivity of drugs in terms of activation/deactivation of com-
lex biological processes in living animals. Consequently, using
nnovative preclinical strategies of optical imaging has allowed
n vivo real-time insight not only in genomics and proteomics
[9] and references 1–6 herein), but also in disease state of ani-
al  models such as the size of cancer lesions or of a remodeled
one [10].
However, one of the main drawbacks of in vivo optical imag-
ng is the signiﬁcant interaction of light with biological tissue due
o scattering and absorption resulting in signiﬁcant light attenua-
ion, blurring and halo effects. This limits the applicability of optical
maging to a depth of a few millimeters or less, especially outside
he so-called optical window in the near infrared (NIR) wavelength
egime (≈600–1000 nm), where light–tissue interaction is minimal
11]. This signiﬁcantly hampers the possibility of deriving quanti-
ative information on dose and/or biological response from optical
maging methods [12,13]. Consequently, only a few attempts have
een published, where quantitative information on biological pro-
esses or disease state has been obtained from inner organs of small
nimals [10]. Compared to all other internal organs, light propa-
ation through the lung is further complicated by the interaction
f light with the numerous air–tissue interfaces due to millions
f alveolar sacks comprising about 90% of the lung volume. This
akes quantitative in vivo ﬂuorescence imaging in the lungs even
ore elusive.
Cryoslicing Imaging has been used as an alternative to in vivo
maging. Herein, a frozen specimen block is imaged and sliced in an
lternate manner as depicted in Fig. A.1 (online supplement). As the
ung has to be excised Cryoslicing Imaging is a time-consuming, ter-
inal procedure, but it provides much better spatial resolution and
an serve as a quantitative veriﬁcation of the in vivo imaging results
14]. Similar systems of varying measurement capabilities, spatial
esolution and sensitivity have been used in the past for validation
f novel imaging modalities like near-ﬁeld thermo-acoustic imag-
ng [15] and ﬂuorescence molecular tomography [10], for anatom-
cal visualization of intramural coronary vasculature [16], to study
io-distribution of molecular probes [17] or GFP-labeled cancer
ells [14], and for single cell visualization and quantiﬁcation [18].
In this study we describe and validate a Cryoslicing Imaging
ethod for quantitative assessment of 3D dose distribution of ﬂu-
rescent substances in the lungs of mice. The main components
f the method are dose-controlled in vivo administration of a ﬂu-
rescent substance into the lungs, sample (lung) preparation as
ell as acquisition and processing of the images. For conversion of
lock face images into single-slice ﬂuorescence images, the effec-
ive attenuation coefﬁcient of frozen (murine) lung tissue was
xperimentally determined and used to account for out-of-plane
uorescence in the block face images. The Cryoslicing Imaging
ethod is validated by linear dose–response curves from lungs
f mice with known amounts of ﬂuorescent nanoparticles and a
uorescence-labeled, molecular drug currently undergoing pre-
linical testing.d Biomedical Analysis 102 (2015) 129–136
2. Material and methods
2.1. Fluorescent substances
For validation of the Cryoslicing Imaging method presented here
known amounts of ﬂuorophore were delivered directly to the lungs
of mice by intratracheal instillation as described below. Two types
of ﬂuorescent substances were used for the experiments, namely
polystyrene nanoparticles (diameter 450 nm)  with the embedded
ﬂuorescent dye Sky Blue (excitation/emission = 670 nm/710 nm;
Kisker Biotech GmbH, Steinfurt, Germany) and a molecular drug
(soluble human Fc receptor IIB) covalently bound to the ﬂuoro-
phore Alexa750 (Ex/Em = 749 nm/775 nm), henceforth referred to
as FcR-Alexa750. Four different concentrations (1:20, 1:60, 1:200
and 1:600 dilutions) of a 1 mg/ml  Sky Blue stock solution were
prepared in pyrogene-free distilled water for intratracheal instil-
lation in mice. Similarly, two  different dilutions (1:20 and 1:40)
of a 1 mg/ml  stock solution of FcR-Alexa750 were prepared in
phosphate buffered saline.
2.2. Animal handling and preparation of the lung
Mice were kept in isolated ventilated cages (IVC-Racks; Bio-
Zone, Margate, UK) supplied with ﬁltered air in a 12-h light/12-h
dark cycle (lights on from 06:00–18:00). Food (standard chow) and
water were available ad libitum. All procedures for animal handling
and experiments were performed in accordance with protocols
approved by the Regierung von Oberbayern (District Government
of Upper Bavaria).
Six FVB-GT mice (13–19 weeks, 2 male, 4 female, 25–35 g) and
seven C57BL/6 mice (age 8–14 weeks, all female, weight 18–27 g)
were used for experiments with Sky Blue and FcR-Alexa750,
respectively. For each mouse strain two  animals were selected
as control mice (without ﬂuorophore). One FVB-GT mouse was
not successfully instilled and hence discarded. Prior to instillation,
mice were anesthetized by intraperitoneal injection of a mixture
of medetomidine (0.5 mg/kg body mass), midazolam (5.0 mg/kg
body mass) and fentanyl (0.05 mg/kg body mass). Animals were
then intubated by a non-surgical technique [19]. A 20G cannula
(Cat. No. 4254112B, B. Braun, Melsungen, Germany) was inserted
10 mm into the trachea and correct placement of the cannula in the
trachea instead of the esophagus was  veriﬁed with a pneumotacho-
graph. Subsequently, a 1 ml  syringe containing 50 l of ﬂuorophore
solution/suspension and 200 l of air was connected to the cannula
and squirted directly into the lungs by intratracheal instillation as
the animal inhaled [20]. The 200 l of air facilitates transport of
the 50 l of liquid into the lung. The actually delivered pulmonary
ﬂuorophore dose of 38.6 ± 5.5 l (mean ± standard deviation; or
±14.2% relative standard deviation) was measured by weighing
the cannula and the syringe before and after the delivery. Thus,
on average only 76% of the invested dose reached the lung, while
the rest remained in the instillation wear and the uncertainty in
pulmonary substance dose would be 14.2%, if the gravimetric anal-
ysis of the instillation wear would not have been performed. Here,
the accuracy of the delivered dose is estimated to be 5% mainly due
to inadvertent loss of small amounts of liquid during handling of
the instillation wear. The maximum instilled mass of dye instilled
into the lungs was  1.9 g (=38.6 l out of a 1:20 diluted 1 mg/ml
stock solution).
The anesthetized mice were sacriﬁced immediately after the
application procedure by exsanguination. Subsequently, a 21G can-
nula was  inserted into the trachea by tracheotomy, the lung wasTemperature compound, VWR  International GmbH, Darmstadt,
Germany) to the cannula and gently infusing 0.5 ml of clear OCT.
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Cryoslicing Imaging the visualization of the ﬂuorophore distribu-
tion in 3D is achieved by stacking the serial ﬂuorescence block
face images of the specimen. Fig. 1a shows a reconstructed frontal
lung slice along the trachea, i.e. in a direction perpendicular to
Fig. 1. 2D projection of 3D distribution of the ﬂuorophore. (a) Frontal slice of the lung
along the trachea obtained from 3D reconstruction using the axial white light reﬂec-
tion slices. The white region shows OCT injected into the airways of the excised lungN. Barapatre et al. / Journal of Pharmaceuti
part from preventing the lung from collapsing, the OCT infusion
lso provides a stable substrate for cryoslicing. The lung was  then
mbedded into a 30 mm diameter cylindrical block using black pig-
ented OCT and placed into a –20 ◦C freezer. The black pigmented
CT reduced scattering of light from the surrounding OCT into the
ung tissue and simpliﬁed automated selection of lung area during
uantitative region-of-interest (ROI) analysis. The lung blocks were
easured in the frozen state by Cryoslicing Imaging. The block face
as imaged at every 100 m step. The slicing thickness was  chosen
t 25 m to maintain the sample integrity. Hence, four slicing steps
ere performed between two consecutive images.
.3. Image processing
Quantitative analysis of the ﬂuorescence images requires care-
ul consideration of measurement biases, out-of-plane ﬂuorescence
nd optical properties of the lung tissue.
.3.1. Background noise subtraction
As with any ﬂuorescence imaging system, multiple types of
cene-, pixel-, and exposure-time-dependent noise and parasitic
ignals contributed to the actual image, including noise from the
CD sensor, ambient light at the emission wavelength, cross-talk
f the ﬁlters, lens imperfections, and tissue auto-ﬂuorescence. Four
ungs with no application of ﬂuorophores (untreated lungs) were
easured with the same setup to account for these biases (system-
tic biases) and to determine the lower limit of detection (statistical
oise). The exposure time of the camera was  kept variable to
rovide optimum signal-to-noise ratio for images with low and
igh signal intensity. The contribution of background signal was
etermined by taking a mean photon count from the corners of
he ﬂuorescence images devoid of any specimen structures. The
ean background counts were found to be linearly dependent on
he exposure time of each image. The offset of the linear ﬁt was
ssumed to be the additive noise (electronic read-out bias and dark
urrent). In order to achieve quantitative ﬂuorophore assessment,
ias corrections and block face to slice intensity inversion were
one with an image processing routine written in MATLAB.
As seen in Eq. (1) the exposure-time-dependent background sig-
al and the electronic noise (Fnoise(texp)) were subtracted from each
uorescence block face image (Fmeas) and then normalized to the
xposure time (texp)
cor =
Fmeas − Fnoise(texp)
texp
(1)
ielding ﬂuorescence photon counts per second as new intensity
ignal.
.3.2. Out-of-plane ﬂuorescence subtraction
The sequence of corrected block face images was inverted into
ingle slice images by subtracting out-of-plane ﬂuorescence from
he block face images according to an empirical algorithm described
y [18]. Brieﬂy, if Fn and Fn−1 represent consecutive corrected block
ace images (Eq. (1)), the ﬂuorescence image attributed to ﬂuoro-
hore located in the nth lung slice (Sn) can be calculated according
o
n = Fn − Fn−1 exp(−effd), (2)
here d and eff are the layer thickness (here: 100 m)  and the
ffective attenuation coefﬁcient of frozen lung tissue, respectively.
he exponential factor in Eq. (2) accounts for light attenuation
f out-of-plane ﬂuorescence within the nth layer according to
ambert–Beer’s law. The stack of single slice images Sn represents
he ﬂuorophore-induced ﬂuorescence intensities throughout the
ntire lung. The dose of the ﬂuorescent marker in the whole lung Biomedical Analysis 102 (2015) 129–136 131
should be proportional to the sum of the ﬂuorescence intensi-
ties from all 100 m slices
(∑
nSn
)
. The conversion factor relating
measured ﬂuorescence intensity to ﬂuorophore mass can be deter-
mined experimentally as described below. For reconstruction and
visualization of 3D distributions of the ﬂuorophore in the lungs
ImageJ and Amira software products were used. The eff of the
frozen lung tissue was obtained experimentally by implanting a
ﬂuorescent point source in an excised murine lung as described in
the online supplement.
2.4. Determination of the intensity–dose conversion factor
As mentioned above, conversion of the measured total ﬂuoro-
phore intensity from all tissue slices into pulmonary ﬂuorophore
mass requires experimental determination of an intensity–mass
conversion factor. This can be accomplished by preparing multi-
ple lungs containing known but different amount of ﬂuorophore
doses. After processing the lungs as described above the measured
total ﬂuorophore intensity can be related to known ﬂuorophore
doses yielding the desired intensity–mass conversion factor for
quantitative Cryoslicing Imaging. If the relationship is linear then
the intensity–mass conversion factor can be obtained by using just
two “reference” lungs, one containing a realistically distributed and
known amount of ﬂuorophore and one without any ﬂuorophore
(autoﬂuorescence of tissue). Of course, using a larger number of ref-
erence lungs will improve the dosimetric accuracy of the method.
Finally, the measured 3D intensity map  is converted into a 3D
ﬂuorophore dose distribution by pixel-wise multiplication of the
intensity map  with the intensity–mass conversion factor.
3. Results
3.1. Lung Cryoslicing Imaging
The apparatus used for Cryoslicing Imaging of the lung is
described in the online supplement and illustrated in Fig. A.1. In(the outside-lung background was removed using an automated mask). (b) Recon-
structed distribution of FcR-Alexa750 as a 3D maximum intensity projection of the
ﬂuorescence channels corresponding to the view presented in panel (a). This indi-
cates the pulmonary distribution of the ﬂuorescence-labeled dye after intratracheal
instillation into the lung.
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Fig. 2. Comparison of the measured ﬂuorescence intensity in the block face to the
calculated ﬂuorescence intensity per slice. The solid line depicts the measured total
(sum over all pixels) block face intensity as the lung is sliced axially. The dot-
ted line represents the net ﬂuorescence from each 100 m thick slice calculated
from the block face images using sub-surface correction according to Eq. (2) with
eff = 10.0 ± 0.6 cm−1. The lung was sliced axially along the orientation of the trachea
starting from the trachea. Clearly, about 90% of the block face ﬂuorescence inten-
sity  of FcR-Alexa750 is due to sub-surface ﬂuorescence and only about 10% of the32 N. Barapatre et al. / Journal of Pharmaceuti
he cutting and imaging during block face imaging. This image is
btained from frontal re-construction of the measured axial RGB
red–green–blue, i.e. white light) reﬂection images. White color
n the airways is due to unpigmented OCT instilled in the lungs
uring cryoﬁxation. The image clearly illustrates the left and the
ight half of the lung and their typical monopodal airway structure
small airways branching-off one main airway). Fig. 1b shows the
ssociated frontal re-construction of the 3D ﬂuorescence marker
istribution for the lung. It depicts a maximum intensity projection
f the ﬂuorescence channel, where increasing brightness correlates
ith enhanced ﬂuorescence-labeled drug dose. As seen from Fig. 1b
pplication of ﬂuorophore by intratracheal instillation preferen-
ially targets the central airways of the lung.
.2. Experimental determination of the effective attenuation
oefﬁcient of lung tissue
As mentioned above for quantitative ﬂuorescence analysis the
lock face images have to be inverted into single slice images taking
nto account out-of-plane ﬂuorescence, which requires knowledge
f the effective attenuation coefﬁcient (eff) of the sample tis-
ue (Eq. (2)). Fig. A.2 (online supplement) shows the decreasing
lock face intensity with increasing distance (100 m increments)
rom a ﬂuorescent point source due to tissue attenuation. Mod-
ling light attenuation in frozen lung tissue according to Beer’s
aw (exponential decay of intensity with increasing distance), eff
as derived from an exponential ﬁt of the data. The resulting eff
alue of 10.0 ± 0.6 cm−1 (at 716 nm)  represents the sum of the
xcitation and the emission attenuation. It also implies that 90.5%
=exp(−10.0 cm−1·0.01 cm)) of the ﬂuorescence intensity emitted
rom the sub-surface layer (Fn−1) is reaching the surface of the
rgan block (Eq. (2)). Consequently, provided the ﬂuorophore is
niformly distributed, about 90% of the measured block face ﬂuo-
escence intensity (Fn) is due to sub-surface ﬂuorescence and only
0% is emitted from the 100 m thick surface layer.
.3. Out-of-plane ﬂuorescence correction of block face images
The sequence of block face images was inverted into single slice
mages by subtracting out-of-plane ﬂuorescence from the block
ace images as described in Section 2. The tissue attenuation was
aken into account with eff = 10.0 ± 0.6 cm−1 (at 716 nm). The axial
istribution of the ﬂuorophore throughout the lung is illustrated
n Fig. 2. The solid line depicts the measured total (sum over all
ixels) block face intensity as the lung is sliced axially. The dot-
ed line represents the net ﬂuorescence from each 100 m thick
lice calculated from the block face images using Eq. (2) with
eff = 10.0 ± 0.6 cm−1. Evidently, both curves show a pronounced,
road peak in the central part of the lung, which is largely due to
he increased cross-sectional area about half way between trachea
nd tip of the lung. Furthermore, Fig. 2 shows that about 90% of
he measured block face light intensity is due to sub-surface light
mission.
Fig. 3 compares the spatial distribution of the sub-surface cor-
ected ﬂuorescence intensity in a 100 m slice (Fig. 3c) with the
easured ﬂuorescence intensity distribution in a single 25 m slice
Fig. 3d) of the same block position. Fig. 3d was obtained with a dif-
erent epi-ﬂuorescence imaging system. During the slicing step a
5 m slice was  taken on a glass slide and imaged at room tem-
erature. Fig. 3c was obtained by attenuating the Fn−1 block face
mage (eff = 10.0 cm−1) and blurring it by a 10 pixel (360 m)
ide Gaussian kernel prior to subtracting it from the Fn block facemage (Fig. 3b). The degree of blurring was experimentally deter-
ined by adjusting the Gaussian kernel such that any ﬂuorescence
ignal from the OCT covered (normally air-ﬁlled) regions of the air-
ays (identiﬁed from Fig. 3a) is eliminated. This approach utilizesmeasured light emanates from the top 100 m thick slice. The elevated ﬂuorescence
levels between 65 and 120 are largely explained by the larger cross-sectional area
of  the lung in this region.
the fact that after subtraction of sub-surface ﬂuorescence the air-
ways should not show any ﬂuorescence signal, as the ﬂuorophore
is deposited on the airway walls and/or is transported deeper into
the tissue, but is not present in the airspace itself. Both the cal-
culated 100 m (Fig. 3c) and the directly measured 25 m slice
image (Fig. 3d) show a similar ﬂuorophore intensity distribution
with more pronounced ﬂuorescence in the left half of the lung and
a similar “hot spot” pattern. However, not all of the hot spots are
matching up and most of the elevated ﬂuorescence traces along
some of the airway channels in Fig. 3c are not seen in Fig. 3d. This
may  be a result of the difference in layer thickness. If airways are
25–100 m large, slicing off a 100 m layer may completely elim-
inate the airway ﬂuorescence in the Fn−1 image. Conversely, the
direct image from a 25 m slice may  not capture any of the ﬂuoro-
phore covering the airway walls. Interestingly, there are also some
cases where ﬂuorescent airway traces can be seen in both Fig. 3c
and d suggesting that in this case the remainder of the airway was
less than 25 m deep.
3.4. Dose–response assessment
Fig. 4a shows the total pulmonary ﬂuorescence intensity as
a function of the intratracheally instilled mass of the ﬂuores-
cent nanoparticles (Sky Blue). It is evident from Fig. 4a that
there is a strong linear correlation (R2 > 0.98) between total ﬂu-
orescence signal and applied ﬂuorophore mass with a slope of
3.03 × 107 counts/s/g. The intercept representing tissue autoﬂuo-
rescence was  corrected for as described below. The repeatability of
this method is ±9% as estimated from the scatter of the data around
the linear curve ﬁt in Fig. 4a. As this value is signiﬁcantly larger than
the estimated accuracy of the pulmonary ﬂuorophore dose (gravi-
metric analysis as described above) we  argue that 9% represents
the accuracy of the Cryoslicing Imaging method.
As an example for a drug–ﬂuorophore conjugate, we  tested the
method with FcR-Alexa750. As experimental drugs are typically
expensive, minimizing drug consumption is essential. Hence, we
performed a single-point calibration with a bare minimum of two
lungs. One untreated lung and one lung with 1.9 ± 0.3 g of the
drug–ﬂuorophore conjugate (FcR-Alexa750), where the uncer-
tainty represents the repeatability of intratracheal dose application
N. Barapatre et al. / Journal of Pharmaceutical and Biomedical Analysis 102 (2015) 129–136 133
Fig. 3. Out-of-plane ﬂuorescence correction. (a) A white light reﬂection image (RGB-color) of the block face of a frozen murine lung with the instilled ﬂuorescence-labeled
drug  (FcR-Alexa750). (b) The corresponding ﬂuorescence intensity from the block face is shown in false colors. (c) The reconstruction of ﬂuorescence contained in the top
100  m slice from the two  adjacent block face images accounting for sub-surface (out-of-plane) ﬂuorescence. (d) Corresponding ﬂuorescence intensity measured directly in
a  thin (25 m)  slice removed from the block face depicted in panel (a).
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Fig. 4. (a) Dose–response curve for ﬂuorescent nanoparticles (Sky Blue) demonstrating the linearity and detection limit of the method. Total pulmonary ﬂuorescence counts
for  different doses of Sky Blue nanoparticles instilled into the lungs of mice are shown. The tissue autoﬂuorescence signal was subtracted. The graph is showing a linear
correlation between the total ﬂuorescence signal from the murine lungs and applied dose of Sky Blue (R2 = 0.98), where the slope of 3.03 × 107 counts/s/g represents the
intensity–mass conversion factor needed for quantitative Fluorescence Imaging of Sky Blue. The horizontal dashed–dotted line represents the experimentally determined limit
of  detection (0.44 × 107 counts/s corresponding to 145 ng Sky Blue). (b) Comparison of optically calculated and gravimetrically determined pulmonary dose of a ﬂuorescence-
labeled drug (FcR-Alexa750) using the intensity–mass conversion factor (5.27 × 108 counts/s/g). The intensity–mass conversion factor was obtained from the slope of
one-point-calibration (circle symbols). It was used to convert the ﬂuorescence signal into drug dose for the two lungs containing about 0.9 g dye (square symbols). The
optically calculated and gravimetrically determined doses are in good agreement. The horizontal dashed line represents the experimentally determined limit of detection
(8.3  ng). The x-error bars represent the repeatability of the drug application procedure (14%). The y-error bars represent the accuracy of the Cryoslicing Imaging method (9%).
The  dashed lines along the linear ﬁt represent the uncertainty in determination of the intensity–mass conversion factor.
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nto the lungs. Assuming linearity and correction for tissue auto-
uorescence (as described below) the calibration line can be forced
hrough the origin yielding an intensity–mass conversion factor of
5.27 ± 0.75) × 108 counts/s/g (Fig. 4b). The validity of the 1-point
alibration method was tested by determining the ﬂuorescence-
ased ﬂuorophore dose for two additional lungs instilled with
.94 ± 0.14 g of the FcR-Alexa750, where the standard devia-
ion indicates the repeatability of intratracheal instillation (14%)
ithout utilizing gravimetric analysis of the instillation wear prior
nd after instillation. Using the intensity–mass conversion fac-
or determined above the inferred doses were 0.78 ± 0.07 g and
.00 ± 0.09 g, where the uncertainty represents the measurement
ccuracy of Cryoslicing Imaging (9%). It is evident from Fig. 4b that
he calculated doses of 0.78 ± 0.07 g and 1.00 ± 0.09 g, which
iffer by −17% and 6% from the gravimetrically determined dose
ordinate; 0.94 ± 0.14 g), respectively, are within the expected
ombined measurement uncertainties of the Cryoslicing Imaging
ethod (9%) and the instillation procedure (14%; here without
ravimetric analysis of the pulmonary drug dose). This conﬁrms
he validity of the 1-point calibration method for FcR-Alexa750.
ence, this method can be used to convert the measured ﬂuo-
escence intensity into ﬂuorophore mass for lungs which have
eceived an unknown amount of drug during preclinical testing,
or instance, via an inhalation procedure.
Finally, the limit of detection of this method was  determined
rom the autoﬂuorescence of four untreated lungs (lungs with-
ut ﬂuorophore). The total pulmonary ﬂuorescence signal from the
ntreated lungs was (1.56 ± 0.15) × 107 counts/s (mean ± SD, n = 4).
he low relative standard deviation of 10% demonstrates the high
egree of stability of the imaging and sample preparation proce-
ure. The mean signal from the untreated lungs represents the
ean tissue autoﬂuorescence and was therefore subtracted from
he data presented in Fig. 4a and b. Typically the limit of detection
s deﬁned as the 3 noise level (3-fold standard deviation) about
he zero point. With the slopes (intensity–mass conversion factors)
etermined in Fig. 4a and b the 3 noise level of 0.44 × 107 counts/s
orresponds to a detection limit of 145 ng and 8.3 ng for Sky Blue
nd FcR-Alexa750, respectively. This analysis shows that all FcR-
lexa750 samples were above the limit of detection. On the other
and, the lowest applied Sky Blue dose of 71 ng is clearly below
he detection limit and should therefore be considered equal to
ero within the statistical limits of the Cryoslicing Imaging method
resented here.
. Discussion
Lung deposition of inhaled substances is a two-sided coin.
harmaceutical agents are used in inhalation therapy, but inad-
ertent inhalation of toxins or over-dosed drugs may  also result in
ealth risks. Both the therapeutic and toxic potential of substances
epends not only on dose, but also on the region of deposition
ithin the lungs [3]. Hence, there is a signiﬁcant interest in moni-
oring the regional deposition of both nanocarriers and (molecular)
rugs. Optical bioimaging has great potential for measuring spa-
ially resolved tissue-delivered drug dose and probing complex
iologic interactions in small animals such as mice. In vivo bioimag-
ng will even allow for longitudinal real-time monitoring of disease
rogression and efﬁcacy of treatment in the same animal, thus
ffering the potential to accelerate basic research and drug dis-
overy and to reduce cost and the required number of animals
21]. In this proof-of-concept study we present and validate ex vivo
ryoslicing Imaging for quantitative 3D assessment of ﬂuorophore
ose in the lungs of mice.
The linearity of quantitative Cryoslicing Imaging can be seen
rom Fig. 4a using ﬂuorescent nanoparticles Sky Blue. This is thed Biomedical Analysis 102 (2015) 129–136
prerequisite for reliable and simple application of this method
even for cost-intensive investigational drugs. An excellent lin-
ear relationship between the measured total ﬂuorescence signal
and the corresponding amount of pulmonary ﬂuorophore sug-
gests that the simple image processing algorithm presented here
provides quantitatively valid data. As the dose–response curve is
linear and has an intercept close to zero (after the autoﬂuores-
cence signal was  subtracted), the intensity–mass conversion factor
for the precious ﬂuorophore–drug conjugate can be obtained by
preparing at least one “reference” lung containing a realistically
distributed and known amount of ﬂuorophore and one without
any ﬂuorophore (autoﬂuorescence of tissue). Of course using a
larger number of reference lungs will improve the dosimetric accu-
racy of the method. As shown here the required reference lung(s)
can be prepared using the intratracheal instillation method com-
bined with gravimetric analysis of the instillation wear described
above.
For validation of the method we  have chosen Sky Blue as surro-
gate drug, because its spectral range is in the NIR optical window
of tissue imaging and its ﬂuorophore is embedded in a polystyrene
latex matrix, which guarantees stable quantum yield independent
of the microenvironment of the Sky Blue nanoparticles. The sit-
uation is potentially more complicated for a ﬂuorescence-labeled
molecular drug, as the covalently bound ﬂuorophore may  inter-
act with proteins and enzymes of the biological matrix which may
change the quantum yield of the ﬂuorescence tracer in an unpre-
dictable way. However, no such complications were observed for
FcR labeled with Alexa750, an experimental drug currently under
preclinical investigation. Applying the 1-point calibration tech-
nique described above, the pulmonary mass doses for two reference
lungs containing known amounts of FcR-Alexa750 was  obtained
by the Cryoslicing Imaging method (Fig. 4b). Taking into account
the accuracy of the Cryoslicing Imaging method and the repeat-
ability of the pulmonary application of reference doses, there is a
good agreement between the ﬂuorescence-based and the known
pulmonary dose. Hence, the Cryoslicing Imaging technique can be
used for quantitative assessment of drug dose in murine lungs.
Obviously, the accuracy of the calibration curve can be improved
by using a larger number of reference lungs. Furthermore, the accu-
racy of the pulmonary dose in the reference lung can be enhanced
from 14% to 5%, if the instillation wear is gravimetrically analyzed
prior and after instillation as described above.
In general the photon yield of a ﬂuorophore, and hence the cor-
responding intensity–mass conversion factor, depends on various
parameters including type of ﬂuorophore, optical properties of the
frozen lung tissue as well as design and operational aspects of the
Cryoslicing Imaging device. As ﬂuorophores are typically used as
labeling agent, the fractional contribution of the ﬂuorophore to the
substance mass strongly determines the intensity–mass conver-
sion factor. Also other effects such as photo-bleaching or (self-)
quenching of the ﬂuorophore will affect the intensity–mass con-
version factor. To account for all of these aspects the Cryoslicing
Imaging technique has to be calibrated for each ﬂuorophore. Since
the experimental conditions, including the tissue optical proper-
ties (eff) are kept constant for all the lungs, the quantiﬁcation
of ﬂuorophore dose is fairly insensitive to any inaccuracy in the
determination of the eff.
Another important aspect is the limit of detection, which was
determined from the variability of the ﬂuorescence signal from
four untreated lungs. The baseline value mainly depends on tissue
autoﬂuorescence, the ambient light in the room and the quality of
the spectral ﬁlters and cross-talk of the ﬁlters due to partial reﬂec-
tion of the excitation light. The 3 variability of the untreated lung
signals deﬁned the limit of detection as 8.3 ng and 144 ng for FcR-
Alexa750 and Sky Blue, respectively. With a maximum applied dose
of 1.9 g, our data document a dynamic measurement range of
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ore than two (229) and one order of magnitude (13) for FcR-
lexa750 and Sky Blue, respectively, i.e.,  pulmonary ﬂuorophore
oses as low as 0.44% and 7.6% of the maximum applied ﬂuorophore
ass can be detected for FcR-Alexa750 and Sky Blue, respectively.
In this proof-of-concept study no efforts were made to improve
he limit of detection. If measurements below the current detec-
ion limit are to be performed, the signal-to-noise ratio could be
mproved by e.g. using low ﬂuorescence animal diet (reduces tis-
ue autoﬂuorescence), complete removal of the blood from the
ungs (hemoglobin is expected to be the main source of autoﬂuo-
escence in the lung) and/or by using different imaging settings, like
ulti wavelength imaging for spectral unmixing of the signal for
mproved removal of auto-ﬂuorescence [17,22]. In addition, narrow
and laser excitation and/or ﬁlters with less cross-talk and a better
ptical shielding of the imaging chamber may  improve sensitivity.
In the method presented here a relatively simple, yet accu-
ate, algorithm for the correction of out-of-plane ﬂuorescence was
pplied, which does not involve direct modeling of light propaga-
ion in the tissue. However, even this correction algorithm is not
ecessary, if only individual slices (instead of block faces) would be
maged. This is typically not done due to technical difﬁculties such
s the softness or brittleness of unfrozen or frozen organ slices,
espectively, which makes it complicated to maintain the struc-
ural integrity of a single lung slice. For a few representative cases,
ndividual 25 m thick lung slices were imaged, but upon touching
he object holder the slice immediately melts and loses its stiff-
ess. As seen from Fig. 3c and d there is good agreement between
he calculated and measured ﬂuorescence distribution.
As perquisite for correct out-of-plane ﬂuorescence correction
he effective attenuation coefﬁcient (eff) of frozen murine lung tis-
ue was experimentally determined as 10.0 ± 0.6 cm−1 (at 716 nm),
hich is relatively close to published values between 11 and
7 cm−1 (at 633 or 790 nm)  for non-frozen lung tissue from various
nimals other than mice [23]. To the best of our knowledge, this is
he ﬁrst experimental eff value for a mouse lung and in particular
or frozen murine lung tissue. A value of eff = 10.0 cm−1 implies
hat for 100 m slices 90.5% of subsurface ﬂuorescence is reach-
ng the surface (out of a depth of 100 m).  This value decreases to
6.9% and 13.5% and 5.0% for a depth of 1 mm,  2 mm and 3 mm,
espectively. As mouse lungs have a typical dimension of 1.5–2 cm,
ost of the light measured off the block face emanates from the
op few millimeters of the sample. Obviously, these values depend
n eff and hence on the chosen wavelength. Our measurements
ere performed at 716 nm,  which lies in the NIR wavelength regime
ca. 600–1000 nm), the so-called optical window where light–tissue
nteraction and hence eff are minimal. While the method pre-
ented here is not limited to this wavelength range, its performance
haracteristics depend on the spectral range. For shorter wave-
engths, the contribution from out-of-plane ﬂuorescence decreases,
ut the tissue autoﬂuorescence increases [23–26] having a negative
ffect on the detection limit. Fluorophores with longer wavelengths
re typically not advisable due to their reduced photon yield and
eterioration of optical properties of many optical components,
hich ultimately results in inferior signal-to-noise ratio and conse-
uently reduced detection limit. Hence, the NIR wavelength regime
ca. 600–1000 nm)  are best suited for quantitative ﬂuorescence
easurements in biological tissue. All of these aspects can be exper-
mentally determined for any given ﬂuorophore according to the
rocedure described in the present study.
Historically, 3D drug distributions have been measured with
adio-imaging methods [27,28]. The main advantage of this
pproach is the relatively low attenuation of radioactive irradi-
tion in biological tissue [29]. However, handling of radioactive
aterials requires special safety measures and – may  be more
mportantly – radioactive methods are not suitable for determi-
ation of the bioactivity of a drug, since they are not sensitive Biomedical Analysis 102 (2015) 129–136 135
to speciﬁc biological responses such as inﬂammation, cytokine
release etc. Matrix-assisted laser desorption ionization imaging
mass spectrometry (MALDI-IMS) has been recently employed for
visualization and quantitative analysis of an antitumor drug in
murine xenografts (10 m thin) with high spatial resolution and
sensitivity [30]. However, MALDI-IMS is not suitable for analyzing
a whole organ such as murine lung, as only a small sample volume
can be measured in a single run. In vivo imaging of internal organs
with visible light typically requires multi-modal approaches, where
optical imaging is combined with e.g. acoustic and/or gamma ray
(CT) tomography. The additional information from the second
imaging mode provides anatomic information which can be used to
improve the 3D reconstruction algorithm by performing modeling
of the propagation of light using organ-speciﬁc optical properties
[31]. While these methods have been used for quantitative assess-
ment of e.g. lung cancer lesions using integrin-targeting ﬂuorescent
probes, accurate 3D ﬂuorophore dose measurements in the entire
lung of mice (or other mammals) have not been performed, yet,
due to the limited penetration depth of light and the particularly
complicated optical properties of the lung. To the best of our knowl-
edge, no optical imaging method for quantitative 3D assessment
of the ﬂuorophore dose in an entire mammalian lung has been
presented, yet. Hence, the method presented here is expected to
provide a valuable tool for accurate determination of both lung
deposited ﬂuorescence-labeled drug dose with a dose resolution
at ng level and – if biosensitive ﬂuorescent probes are used – the
corresponding bioactivity of the drug.
5. Conclusions
This proof-of-concept study has shown that Cryoslicing Imaging
can be used for quantitative 3D dose assessment of ﬂuorescence-
labeled drugs in the lungs of mice. The estimated measurement
accuracy is 9% and the limit of detection was 144 and 8.3 ng for the
ﬂuorescent nanoparticles (Sky Blue) and ﬂuorophore–drug conju-
gate (FCR-Alexa750) used here, respectively. This is sufﬁciently
low for many applications including assessment of dose and, pos-
sibly, bioactivity of inhaled drugs and nanocarriers into the lungs of
mice. This method has the potential to serve as an accurate refer-
ence method for the development and validation of technologically
more challenging quantitative in vivo imaging methods.
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